Real-World Utilization of Palbociclib as First-Line Treatment for Canadian HR+/HER2− Women with Metastatic Breast Cancer: Results from PALCAN Study
Current Oncology · 2026
DOI: 10.3390/curroncol33020081 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, 2026. Verfasst von Daniel Rayson und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Dalhousie University, Halifax, NS B3H 2Y9, Canada. Hauptthemen laut MEDLINE: Pyridines, Breast Neoplasms, Piperazines, Antineoplastic Agents. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer Canada ULC.
Abstract (Originalsprache)
Canadian real-world data (RWD) regarding palbociclib as a first-line therapy for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer (MBC) is limited. The PALbociclib CANadian (PALCAN) study examined palbociclib utilization patterns as first-line treatment for HR+/HER2− MBC using Alberta health administrative data. The final PALCAN cohort included 472 female patients with a median age of 64 years and a median follow-up time of 22.8 months (IQR: 0.7–88.2). The median (95% CI) duration of treatment was 13.8 (12.7–15.1) months in the overall cohort (IQR: 5.6, 24.8 months), and the probability of treatment discontinuation within the first year was 45%. Aromatase inhibitors (AIs) and fulvestrant were the accompanying endocrine therapies (ETs) in 83% (N = 393) and 14% (N = 64) (15 with unknown accompanying therapy) of patients, respectively. The median duration of treatment for patients receiving an AI as an accompanying therapy was 15.1 (13.6–17.4) months and 7.9 months (5.8–12.6) for patients receiving fulvestrant, which may suggest endocrine resistance in the latter group. The PALCAN data provides insights into practice patterns and the effectiveness of palbociclib as a first-line therapy in female patients with HR+/HER2− breast cancer in the Canadian real-world setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Medical Oncology, Dalhousie University, Halifax, NS B3H 2Y9, Canada.
- Pfizer Canada ULC, Kirkland, QC H9J 2M5, Canada.
- IQVIA Solutions Canada, Kirkland, QC H9J 2M5, Canada.
- Oncology Outcomes Research Program, University of Calgary, Calgary, AB T2N 4N1, Canada.
ORCID-Profile: Daniel Rayson, Ryan Ng, Sasha Lupichuk
Förderung
- Pfizer Canada ULC
Zitieren
APA
Rayson, D., Bertin, J., Lemelin, M., Tong, M., Ng, R., Ding, P., Cheung, W. Y., Sharma, A., On, P. V., Feugère, G., & Lupichuk, S. (2026). Real-World Utilization of Palbociclib as First-Line Treatment for Canadian HR+/HER2− Women with Metastatic Breast Cancer: Results from PALCAN Study. Current Oncology. https://doi.org/10.3390/curroncol33020081
Vancouver
Rayson D, Bertin J, Lemelin M, Tong M, Ng R, Ding P, et al. Real-World Utilization of Palbociclib as First-Line Treatment for Canadian HR+/HER2− Women with Metastatic Breast Cancer: Results from PALCAN Study. Current Oncology. 2026. doi:10.3390/curroncol33020081
BibTeX
@article{Rayson2026,
author = {Rayson, Daniel and Bertin, Jonathan and Lemelin, Maxim and Tong, Madeline and Ng, Ryan and Ding, Philip and Cheung, Winson Y and Sharma, Arushi and On, Phu Vinh and Feugère, Guillaume and Lupichuk, Sasha},
title = {Real-World Utilization of Palbociclib as First-Line Treatment for Canadian HR+/HER2− Women with Metastatic Breast Cancer: Results from PALCAN Study},
journal = {Current Oncology},
year = {2026},
doi = {10.3390/curroncol33020081}
}
EUVIMED